Analyst Reco. Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:08:12 2025-07-09 pm EDT			5-day change	1st Jan Change
11.34 ^USD	+4.47%		+3.42%	-4.10%

Jun. 25	Roivant Sciences Insider Sold Shares Worth $1,145,000, According to a Recent SEC Filing	MT
Jun. 10	Roivant Sciences Ltd. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04:00 PM

Analyst Reco.

Piper Sandler Adjusts Price Target on Roivant Sciences to $22 From $20, Maintains Overweight Rating	24-07-10	MT
Deutsche Bank Raises Roivant Sciences' Price Target to $15 From $14, Maintains Buy Rating	24-04-03	MT
Goldman Sachs Raises Roivant Sciences' Price Target to $18 From $16, Maintains Buy Rating	24-04-03	MT
HC Wainwright Raises Roivant Sciences Price Target to $18 From $17, Maintains Buy Rating	24-04-03	MT
Wolfe Research Initiates Roivant Sciences With Outperform Rating, $17 Price Target	24-02-15	MT
Deutsche Bank Initiates Coverage on Roivant Sciences With Buy Rating, $14 Price Target	23-12-12	MT
Goldman Sachs Raises Roivant Sciences Price Target to $16 From $14, Maintains Buy Rating	23-09-27	MT
HC Wainwright Adjusts Roivant Sciences Price Target to $18 From $15, Maintains Buy Rating	23-06-29	MT
Truist Securities Adjusts Price Target on Roivant Sciences to $23 From $19, Maintains Buy Rating	23-06-23	MT
BofA Securities Starts Roivant Sciences at Neutral With $10.50 Price Target	23-06-08	MT
JPMorgan Adjusts Roivant Sciences Price Target to $14 From $12, Maintains Overweight Rating	23-05-18	MT
HC Wainwright Adjusts Price Target on Roivant Sciences to $15 From $14, Maintains Buy Rating	23-05-17	MT
JPMorgan Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Overweight Rating	23-02-13	MT
Goldman Sachs Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	23-01-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $14 From $11, Maintains Buy Rating	23-01-05	MT
SVB Securities Adjusts Price Target on Roivant Sciences to $10 From $8, Maintains Outperform Rating	22-12-19	MT
Citigroup Adjusts Price Target on Roivant Sciences to $11 From $10, Maintains Buy Rating	22-11-15	MT
Citigroup Raises Roivant Sciences' Price Target to $10 From $9, Maintains Buy Rating	22-08-16	MT
SVB Securities Adjusts Roivant Sciences' Price Target to $7 from $6, Keeps Outperform Rating	22-06-29	MT
Goldman Sachs Adjusts Roivant Sciences Price Target to $12 From $15, Maintains Buy Rating	22-05-24	MT
Goldman Sachs Lowers Roivant Sciences; Price Target to $12 From $15, Maintains Buy Rating	22-05-24	MT
SVB Securities Initiates Roivant Sciences at Outperform With $6 Price Target	22-05-23	MT
Cantor Fitzgerald Initiates Roivant Sciences at Overweight with $15 Price Target	22-04-29	MT
Goldman Sachs Starts Roivant Sciences at Buy With $15 Price Target	21-12-15	MT
HC Wainwright Initiates Roivant Sciences at Buy With $14 Price Target	21-11-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Roivant Sciences Ltd.

Equities

ROIV

BMG762791017

Pharmaceuticals

Analyst Reco.

Filters